Who we are

We aspire to be a leading people and process driven global pharmaceutical company. We’re the fastest-growing pharmaceutical company in the neuro-psychiatry segment in India with innovative brands in dermatology, nutraceuticals and cardio-diabetics. 

What we do

We believe everyone deserves access to world-class medicine. Through innovation, exceptional talent, and efficient processes, we make healthcare affordable and accessible to all

Our Story

2007 – A focused beginning in CNS

Linux Laboratories was founded with a clear focus on the central nervous system (CNS) segment. Working closely with psychiatrists and neurologists, we set out to address unmet needs in mental health and neuro‑psychiatry across India.

2018 – Expanding our CNS leadership

To serve more doctors and patients in neuro‑psychiatry, we launched Linux Infina, our second CNS business unit. This strengthened our presence in the segment and allowed us to bring a wider range of evidence‑based therapies to market.

2019 – Building our own manufacturing strength

With the creation of Linux Lifesciences Manufacturing Co, we invested in our own WHO‑cGMP compliant manufacturing facility. This step gave us greater control over quality, supply reliability and innovation in formulations.

2020 – Stepping onto the global stage

We formed our International Business Division, taking Linux brands and capabilities beyond India. This marked the beginning of our journey as a global pharmaceutical player.

2021 – Fuel for accelerated growth & portfolio expansion

In 2021, Tata Capital invested in Linux Laboratories, validating our business model and future potential. The same year, we diversified into aesthetics and skin health through the acquisition of the Biomedica cosmetic business, further broadening our specialty portfolio.

2022 – Strengthening dermatology

We deepened our presence in dermatology by acquiring key derma brands from India Bulls. This enabled us to offer a more comprehensive range of solutions to dermatologists and patients.

2025 – Scaling CNS and entering Cardio‑Diabetics

We continued to reinforce our CNS leadership with the launch of Linux INTEGRA, our third CNS business unit. In parallel, we entered the high‑impact Cardio‑Diabetic segment by acquiring established brands from CIPLA, expanding our reach into chronic lifestyle diseases by launching META, our Cardio- Diabetic business unit

Manufacturing

Established in 2019,Linux Lifesciences Private Limited is a wholly owned manufacturing subsidiary of Linux Laboratories. We offer a comprehensive range of manufacturing services at our state-of-the-art facilities located at Pondicherry in southern India with clients from India and abroad. Our plants are WHO-cGMP certified & equipped with the latest technology, allowing us to provide innovative solutions for even the most complex pharmaceutical products. We work closely with our clients to understand their unique requirements and provide customized solutions that deliver results. 

Partner With Us

Partnering with us means that you can focus on your core competencies while we take care of your manufacturing needs. We are committed to delivering exceptional value to our clients, and our cost-effective solutions ensure that you get the most out of your investment. So, if you are looking for a reliable and experienced third-party pharmaceutical manufacturer, look no further. Contact us today to learn more about our services and how we can help you bring your products to market quickly and efficiently.

Contact Us